Quotient Therapeutics is pioneering a transformative approach to drug discovery through its innovative Somatic Genomics platform. This platform leverages advanced sequencing technology to explore the extensive variations within the somatic genome, which encompasses the trillions of divergent genomes present in human tissues. By employing a four-step process—phenotyping, isolation, genotyping, and computation—Quotient identifies and isolates cells from diseased tissues, allowing for the precise characterization of somatic mutations that drive disease pathology. This method not only enhances the understanding of the genetic underpinnings of diseases but also facilitates the identification of intrinsically validated therapeutic targets, significantly improving the potential for developing effective treatments.

The advantages of Quotient's Somatic Genomics platform are substantial, as it can uncover novel genetic targets that traditional population genetics approaches may overlook. By focusing on the somatic mutations that occur within individual cells, the platform can make discoveries using a limited number of clinical samples, which is particularly beneficial for studying rare diseases or specific disease subtypes. The high-resolution genotyping capabilities enable the characterization of genes at the level of protein amino acids, providing critical insights that guide the development of impactful therapeutics. This revolutionary approach not only enhances the understanding of disease biology but also opens up new avenues for creating transformative medicines that can cure, prevent, or reverse various health conditions.

United States

Our Somatic Genomics platform unveils a new universe of genetic variation to create transformational medicines. Learn more at Quotient-Tx.com

Quotient Therapeutics

Company Details